OTCPK:BICX

Stock Analysis Report

Executive Summary

BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Risks

  • BioCorRx has significant price volatility in the past 3 months.
  • BioCorRx is not covered by any analysts.

Share Price & News

How has BioCorRx's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.3%

BICX

-0.04%

US Healthcare

-0.6%

US Market


1 Year Return

-67.9%

BICX

-9.1%

US Healthcare

0.6%

US Market

BICX underperformed the Healthcare industry which returned -9% over the past year.

BICX underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

BICXIndustryMarket
7 Day7.3%-0.04%-0.6%
30 Day-2.9%-0.5%2.2%
90 Day-27.4%-1.6%1.1%
1 Year-67.9%-67.9%-7.7%-9.1%2.9%0.6%
3 Year-15.2%-15.2%29.6%24.3%44.6%35.2%
5 Year-71.6%-71.6%66.1%56.2%61.9%44.2%

Price Volatility Vs. Market

How volatile is BioCorRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioCorRx undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether BioCorRx is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioCorRx has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BICX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through BioCorRx regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is BioCorRx expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioCorRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BICX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioCorRx's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has BioCorRx performed over the past 5 years?

-14.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioCorRx does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare BioCorRx's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BioCorRx's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BioCorRx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if BioCorRx has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if BioCorRx improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is BioCorRx's financial position?


Financial Position Analysis

BioCorRx's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

BioCorRx's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BioCorRx has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if BioCorRx's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

BioCorRx has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BioCorRx has sufficient cash runway for 2.2 years based on current free cash flow.

BioCorRx has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 4.7% each year.


Next Steps

Dividend

What is BioCorRx's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioCorRx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioCorRx's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioCorRx has not reported any payouts.

Unable to verify if BioCorRx's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioCorRx has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BioCorRx's salary, the management and board of directors tenure and is there insider trading?

5.5yrs

Average board tenure


CEO

Brady Granier (47yo)

3.3yrs

Tenure

US$1,477,753

Compensation

Mr. Brady James Granier has been the Chief Executive Officer and President of BioCorRx Inc. since June 10, 2016. Mr. Granier served as the Chief Operating Officer and Secretary of BioCorRx Inc. since June  ...


CEO Compensation Analysis

Brady's remuneration is higher than average for companies of similar size in United States of America.

Brady's compensation has increased whilst company is loss making.


Board Age and Tenure

5.5yrs

Average Tenure

51yo

Average Age

The tenure for the BioCorRx board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$3,000,00017 Apr 19
Joseph Galligan
EntityIndividual
Shares200,000
Max PriceUS$15.00
BuyUS$3,000,00004 Apr 19
Louis Lucido
EntityIndividual
Role
Member of the Board of Directors
Director
Shares200,000
Max PriceUS$15.00

Ownership Breakdown


Management Team

  • Bal Brar (82yo)

    Senior Vice President of Drug Development

    • Tenure: 0yrs
  • Lourdes Felix (51yo)

    CFO, COO & Director

    • Tenure: 6.9yrs
    • Compensation: US$1.47m
  • Brady Granier (47yo)

    President

    • Tenure: 3.3yrs
    • Compensation: US$1.48m
  • George Fallieras

    Medical Consultant

    • Tenure: 0yrs

Board Members

  • Louis Lucido (71yo)

    Director

    • Tenure: 0.5yrs
  • Ben Price (63yo)

    Member of Advisory Board

    • Tenure: 5.5yrs
  • Lourdes Felix (51yo)

    CFO, COO & Director

    • Tenure: 6.9yrs
    • Compensation: US$1.47m
  • Brady Granier (47yo)

    President

    • Tenure: 3.3yrs
    • Compensation: US$1.48m
  • Kent Emry (51yo)

    Director

    • Tenure: 6yrs
    • Compensation: US$362.22k
  • Mark Sorrentino

    Member of Advisory Board

    • Tenure: 5.5yrs
  • Rick Haatvedt

    Member of Advisory Board

    • Tenure: 5.5yrs
  • David Gastfriend

    Member of Scientific Advisory Board

    • Tenure: 0.6yrs
  • Evgeny Krupitsky

    Member of Scientific Advisory Board

    • Tenure: 0.6yrs
  • George Woody

    Member of Scientific Advisory Board

    • Tenure: 0.6yrs

Company Information

BioCorRx Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioCorRx Inc.
  • Ticker: BICX
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$10.402m
  • Shares outstanding: 3.06m
  • Website: https://www.biocorrx.com

Number of Employees


Location

  • BioCorRx Inc.
  • 2390 East Orangewood Avenue
  • Suite 575
  • Anaheim
  • California
  • 92806
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BICXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2011

Biography

BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. It distributes and licenses BioCorR ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:32
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.